LABORATOIRES EUROMEDIS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.14 EUR | 0.00% |
|
-0.96% | -22.18% |
| 2023 | Euromedis Groupe Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Euromedis Groupe Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -22.18% | 12.66M | - | ||
| -7.03% | 180B | C+ | ||
| -6.32% | 99.21B | C | ||
| -6.15% | 66.25B | A | ||
| -10.62% | 44.74B | B- | ||
| +8.34% | 43.82B | B- | ||
| +11.38% | 41.96B | B+ | ||
| +11.64% | 28.98B | B | ||
| +17.31% | 24.07B | A- | ||
| -8.87% | 23.5B | A- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALEMG Stock
- Ratings Laboratoires Euromedis
